Oncotarget

Research Papers:

Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma

Shan Xu, Yanxin Yu, Jinfeng Rong, Defeng Hu, LiJun Zhang, Shaozhi Fu, Hongru Yang, Juan Fan, Linglin Yang and Jingbo Wu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:31355-31367. https://doi.org/10.18632/oncotarget.15565

Metrics: PDF 699 views  |   HTML 1045 views  |   ?  


Abstract

Shan Xu1,*, Yanxin Yu1,*, Jinfeng Rong1, Defeng Hu1, LiJun Zhang2, Shaozhi Fu1, Hongru Yang1, Juan Fan1, Linglin Yang1 and Jingbo Wu1

1Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, P. R. China

2Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Jingbo Wu, email: wjb6147@163.com

Keywords: nasopharyngeal carcinoma, ERCC1, BRCA1, induction chemotherapy, cisplatin

Received: July 13, 2016    Accepted: January 26, 2017    Published: February 21, 2017

ABSTRACT

In this study, we examined ERCC1 and BRCA1 expression and clinical outcome of 201 phase-III-IV nasopharyngeal carcinoma patients who were treated with cisplatin-based induced chemotherapy and concurrent radiochemotherapy. The chemotherapy response rate of BRCA1 and BRCA1+ patients was 73.6% and 55.8%, respectively. In addition, the chemotherapy response rate of ERCC1 and ERCC1+ patients was 76.9% and 56.6%, respectively. In patients’ tissues, ERCC1 expression associated with BRCA1 expression. The chemotherapy response rate of BRCA1 and ERCC1 patients was (82.1%) and higher than that of other groups (range 52.4-73.1%). The radiochemotherapy response rate of BRCA1 and ERCC1 patients was higher than that BRCA1+ and ERCC1+ patients. BRCA1 and ERCC1 patients showed higher 3-year overall survival, failure-free survival, locoregional failure-free survival and distant failure-free survival compared to BRCA1+ or ERCC1+ patients. Moreover, the 3-year overall survival, failure-free survival and distant failure-free survival of the BRCA1 and ERCC1 group were higher than that of other groups. TNM stage, ERCC1 expression and the correlation between BRCA1 and ERCC1 expression seemed significant overall survival factors. In conclusion, in nasopharyngeal carcinoma patients, ERCC1 and BRCA1 may be a predictor of response to platinum-based chemotherapy and concurrent radiochemotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15565